Background: Due to current controversies regarding the effect of age on response to treatment in asthmatic patient, the present study was performed on patients referred with acute asthma attack for further evaluation of this matter. Materials and Methods: In this study 138 patients with severe persistent asthma were enrolled and divided into two categories of young (age ≤35 yrs; 82 cases, mean age = 25.2±7.3 years) and elderly subjects (≥50 yrs; 56 cases, mean age 57.4±6.4 years). Response to treatment was determined by pulmonary function tests.
INTRODUCTION
Various studies have demonstrated that adrenergic system activity is blunted with aging (2-4). For instance, response to isoproterenol, propranolol, and salbutamol declined significantly in the elderly (2) (3) (4) (5) .It has been suggested that the mechanism of altered beta-adrenergic sensitivity in the elderly is related to reduction of betareceptor affinity for agonists (6) . It has been suggested that aging is associated with reduction in beta-adrenergic responsiveness (7) .
Limited studies are available that evaluate the effects of age on bronchodilator response in asthmatic patients (8, 9) . Rodrigo et al. in a study that was conducted on patients with acute asthma concluded that age is not a predictor of response to beta-agonists (9) . Parker reported that aging does not affect bronchodilator response to betaagonists following methacholine-induced bronchoconstriction (10).
TANAFFOS
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Tanaffos 2012; 11 (2) : [16] [17] [18] [19] [20] [21] Kradjan et al. reported that both albuterol and ipratropium are effective bronchodilators in young and old asthmatic subjects, and age is not a predictor of response to either drug (8) . In another study, Bellia et al. reported that in asthma, aging is associated with a reduced acute responsiveness to bronchodilators (11) . They also concluded that patients with early-onset asthma (starting before the age of 40 years), compared to late-onset asthma (starting after 40 years of age) usually have a less reversible airway obstruction and poorer response to pharmacotherapy (11) . In asthma, the response pattern is also related to allergy and age. Allergic patients and patients under 60 were more likely to respond better to salbutamol than non-allergic and older patients (12) .
The purpose of this study was to evaluate the effects of age on treatment response in two groups of patients with acute asthma and different age range, which were referred to our clinic.
MATERIALS AND METHODS
This study was carried out on 138 patients in a private clinic who were treated for severe persistent asthma, (2) : [16] [17] [18] [19] [20] [21] In an earlier study (17) , the percentage change of FEV1 after two weeks of treatment was 63±13%. Estimation from power and sample size calculations show that the minimum number of samples in each group was 56 subjects that was sufficient to detect an 8% difference with α = 5% and β = 0.1 (i.e., with 90% power).
Data are presented as mean ± SD in parentheses.
Baseline data of the two groups were compared by t test for independent samples. A p-value <0.05 was considered significant for all statistical tests.
RESULTS
Out of 138 patients that completed the study, 82 were young with a mean age of 25.2±7.3 yrs; (41 males, 41 females), and 56 were elderly with a mean age of 57.4±6.4 yrs; (35 males, 21 females). The baseline characteristics of studied patients are presented in Table 1 . There were no significant differences regarding baseline FEV1 level (% predicted) before treatment between the two groups of young and elderly patients. Table 2 summarizes the value of pulmonary function tests after treatment in both groups. After treatment, mean FEV1 improved significantly in both groups in comparison with its baseline values (p<0.001).
As shown in Table 2 , there were no significant differences between two groups regarding the mean± SD As shown in Table 2 , although the mean± SD percentage changes of FEV1 in young patients was more than in the elderly, only in female subjects it was statistically significant (p = 0.015). The percentage change of FEV1 in male subjects was not statistically significant (p= 0.721). In another study, the age range of patients with acute asthmatic attack was about 30-35 years, and the average value of FEV1 was 30% predicted (18) . In the present study, the baseline predictable FEV1 value at the same time was higher; it was 46% and 46.36% in young and elderly patients, respectively. This difference was related to the method of patient selection, because the studied subjects mostly referred to private clinics. In the current study, patients were divided into two groups: the young (age≤ 35 years), and the elderly (≥ 50 years). The cut-off age in our study was similar to the mean age of patients with acute asthma at presentation to the emergency room (9, (19) (20) (21) .
The goals of asthma therapy in elderly patients are not different from those in younger asthmatic patients (22) . In order to eliminate bias related to the degree of airway obstruction, we used the formula "percentage of possible improvement" to express the actual improvement.
By using this formula, there was no significant difference between two age groups, in response to bronchodilator with respect to age. In this study, although the percentage changes of FEV1, in comparison with the baseline in young male and female asthmatic patients were higher than the changes in the elderly, only in the latter groups it was statistically significant (p=0.015). Adrenergic responses suppress with aging, and old patients in comparison with young subjects need higher doses of isoproterenol or propranolol for regulation of heart rate (3). The elderly have reduced beta-adrenergic sensitivity to agonists, which is related to reduced betareceptor affinity (6) . Aging decreases responsiveness in several receptor systems, including the beta-adrenergic receptor system (7) . The response to treatment with ipratropium and salbutamol is related to age. In a study by We conclude that in severe persistent asthma age is not a predictor of response to treatment.
